in the absence of a submission from the holder of the marketing authorisation:
iptacopan (Fabhalta®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice193KB (PDF)
Medicine details
- Medicine name:
- iptacopan (Fabhalta)
- SMC ID:
- SMC2889
- Indication:
Treatment of adult patients with complement 3 glomerulopathy (C3G) in combination with a renin-angiotensin system (RAS) inhibitor, or in patients who are RAS-inhibitor intolerant, or for whom a RAS inhibitor is contraindicated
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 December 2025